news – page 7 – eisai china lnc.-爱游戏(ayx)中国官方网站

news – page 7 – eisai china lnc.-爱游戏(ayx)中国官方网站

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it was selected as the winner of the tokyo governor prize for corporate governance of the year® 2021, which is an award program organized by the japan association of corporate directors (jacd; chairman: yoshihiko miyauchi). the award ceremony was held on january 31, 2022.

the awards have been established to recognize the companies which have achieved and maintained the medium to long term profitability by implementing good corporate governance, since 2015. among the eligible companies for selection of the corporate governance of the year 2021, the tokyo governor prize goes to a company which has excellent corporate governance and also practices esg activities such as environmental activities, women empowerment, initiatives for diversity and work style reforms.

commenting on the reason for selecting eisai, mr. eiichiro kodama, director general for global financial city strategy, office of the governor for policy planning, tokyo metropolitan government stated, “eisai is a pioneer in incorporating its corporate philosophy into the articles of incorporation and practicing “purpose management.” with regard to corporate governance, eisai makes the most of its status as a company with a nomination committee, etc., system to clearly separate management oversight and business execution, and places great importance to dialogue with its stakeholders including patients. in terms of esg, eisai is a signatory to the united nations global compact and actively participates in climate change-related initiatives such as “re100” and the japan climate initiative. in addition, eisai is taking on the challenge of quantifying values that do not appear on the balance sheet, such as investments in human capital, with attempting to select kpis related esg including the ratio of women in management positions, analyze its relationship with pbr (price book-value ratio), and utilize the verification results for engagement with investors. eisai is actively working to tell the story of the cause-and-effect relationship between the esg initiatives and the enhancement of corporate value, thus taking on the extremely important challenge to visualize invisible value, embody the value of esg, and disseminate them.”

eisai defines its corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides” in the articles of incorporation, and shares it with its stakeholders. eisai calls this philosophy the human health care (hhc) philosophy, in one word, and believes that practicing philosophical management based on the hhc philosophy will contribute to achieving sustainable development goals (sdgs) and further enhance its corporate value.

eisai is committed to further strengthening its corporate governance in order to realize the hhc philosophy.

10 year anniversary event of the public-private partnership “london declaration”

 

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that its ceo haruo naito participated in the online event entitled “100% committed to end ntds” celebrating the 10th anniversary of the london declaration, an international public-private partnership to eliminate neglected tropical diseases (ntds), on january 27, 2022. ceo naito represented pharmaceutical companies and highlighted the achievements of ntds elimination activities by the industry and successes achieved by multi-sectoral partnerships. he also expressed eisai’s continued support for the elimination of ntds towards the achievement of ntd road map 2021-2030 launched by the world health organization (who) last year. the 10th anniversary event aimed to recognize a decade of progress since the london declaration, to confirm the strong commitment of stakeholders to continue the efforts for ntds, and to strengthen endorsements from stakeholders to the kigali declaration on ntds, the successor of the london declaration which will be unveiled at the commonwealth heads of government meeting (chogm) scheduled for june 2022 in kigali, the capital of the republic of rwanda.

tremendous achievements have been made through public-private partnership since the launch of the london declaration to 2020. the pharma industry has contributed to the elimination of ntds via supply of medicines which resulted in donation of 13 billion high-quality treatments. forty-three countries have eliminated at least one ntd and 600 million people no longer require interventions against ntds. despite such progress, more than 1.7 billion people remain threatened by ntds.

in the event, ceo haruo naito said “our initiatives toward ntds elimination are rooted in the pharmaceutical company’s fundamental mission to deliver medicines to those who need them to treat illness and save lives. while r&d for ntds treatments have become more active after the london declaration, establishment of agile and flexible regulatory approval system as well as expansion of funding which leverages public-private partnership will be required to accelerate further innovations. utilization of digital technologies such as remote medicine will help ensure delivery of and access to healthcare service under the vulnerable social infrastructure.”

under the london declaration, eisai has been manufacturing and supplying diethylcarbamazine (dec) tablets, one of the lymphatic filariasis (lf) treatments, free of charge to the who for the elimination of lf. to date, 2.05 billion dec tablets manufactured at eisai’s vizag plant in india have been supplied to 29 countries (as of january 2022). although lf has been eliminated in 17 countries and the number of infected people has declined by 74% since 2000, 860 million people worldwide are still exposed to the risk of infection. eisai is committed to providing dec tablets for free to endemic countries that need dec until lf is eliminated in these countries. in addition to the supply of dec tablets, eisai is working on various initiatives such as support for the mass drug administrations (mda), disease awareness and improvements in sanitation.

furthermore, eisai is proactively engaged in development of new treatments for ntds through partnerships with global research organizations. utilizing the funding from the global health innovative technology fund (ghit fund) and others, eisai is conducting joint development of new treatments such as a new treatment for lf in collaboration with the liverpool school of tropical medicine and the university of liverpool as well as treatments for mycetoma and leishmaniasis in collaboration with the drugs for neglected diseases initiative (dndi).

eisai commits to the kigali declaration and strengthens collaborations with global partners to tackle ntds towards the achievement of ntd road map 2021-2030.

based on human health care (hhc) philosophy, eisai seeks to contribute to the health and welfare of people in developing and emerging countries. once they recover their health, they can resume productive activities, which will in turn contribute to economic development and expansion of the middle-income class. eisai considers this to be a long-term investment in creating the markets for the future. eisai is actively engaged in leveraging partnerships with governments, international organizations, academia, and non-profit private sector organizations to accelerate the development of new treatments for infectious diseases including ntds and facilitate initiatives to improve access to medicine such as support for mdas and disease awareness activities. through these initiatives, eisai seeks to further contribute to patients and their families worldwide and increase the benefits that health care provides.

 

media inquiries:

public relations department,

eisai co., ltd.

81-(0)3-3817-5120

 

[notes to editors]

1. about neglected tropic diseases (ntds)

neglected tropic diseases (ntds) include 20 diseases that the who identifies as tropical diseases which human race must overcome. more than 1.7 billion people living in the poorest and most marginalized communities worldwide are exposed to the risk of ntds infection. the spread of ntds is mainly caused by poor hygienic conditions associated with poverty. infections from these diseases may result in serious physical impairment and this often results in normal economic and social activities becoming highly challenging to the individual. in the worst cases, ntds may also result in death. the prevalence of ntds is a stumbling block to economic growth for developing and emerging countries and represents a serious issue for these regions.

the following 20 ntds have been designated by who for control or elimination: dengue and chikungunya, rabies, trachoma, buruli ulcer, yaws (endemic treponematoses], leprosy (hansen’s disease], chagas disease, human african trypanosomiasis (sleeping sickness], leishmaniasis, taeniasis / cysticercosis, dracunculiasis (guinea-worm disease), echinococcosis, food-borne trematodiases, lymphatic filariasis, onchocerciasis (river blindness], schistosomiasis, soil-transmitted helminthiases, mycetoma, scabies and other ectoparasites, and snakebite envenoming.

 

2. about london declaration on neglected tropical diseases

on january 30, 2012, the ceos of 13 pharmaceutical companies*, the bill & melinda gates foundation, who, the u.s. agency for international development (usaid), the u.k. department for international development (dfid), the world bank, and officials from ntd-endemic countries gathered in london to pledge their support for a coordinated effort to combat 10 ntds**. the london declaration represents the largest international public-private partnership in the field of global health to date, and unlike past approaches undertaken by an individual organization or for a single disease, the group has committed itself to working collaboratively in an effort to comprehensively tackle issues pertaining to drug supply, distribution, development, and implementation programs as it seeks to more effectively combat ntds.

commemorating the london declaration, january 30 has been designated as the world ntd day since 2020 and campaigns are held worldwide to light up the iconic landmarks and monuments in orange and purple, the symbol colors of ntds. eisai is sponsoring the light up of tokyo tower to raise disease awareness and disseminate the importance of eliminating ntds. (please click for the details of the world ntd day.)

* abbvie, astrazeneca, bayer, bristol-myers squibb, eisai, glaxonsmithkline, gilead, johnson & johnson, merck (merck kgaa: germany), merck sharp & dhome, novartis, pfizer, sanofi

** guinea worm disease, lymphatic filariasis, blinding trachoma, sleeping sickness (human african trypanosomiasis], leprosy, soil-transmitted helminthes, schistosomiasis, river blindness, chagas disease, and visceral leishmaniasis

 

3. about kigali declaration on neglected tropical diseases

as the successor of the london declaration on ntds launched in 2012, the kigali declaration represents a collective commitment from stakeholders to fight against ntds. with the endorsements from stakeholders being initiated at the online event entitled “100% committed to end ntds”, a campaign to commemorate the 10th year anniversary of the london declaration held on january 27, 2022, the kigali declaration will be unveiled at the commonwealth heads of government meeting (chogm) scheduled for june 2022 in kigali, the capital of the republic of rwanda. to achieve the who’s ntd roadmap 2021-2030, the kigali declaration aims to tackle ntds comprehensively and sustainably by sustaining a multisectoral and multidisciplinary approach through public-private partnership, strengthening country ownership including establishment of local health system and domestic financing, accelerating research and development of treatments and diagnostics  for ntds and ensuring equitable access to these ntds related products and services.

 

4. about lymphatic filariasis

lymphatic filariasis (lf) is an ntd transmitted to humans via carrier mosquitoes. lf causes lymphatic dysfunction and can lead to the swelling of body parts such as legs, and cause severe pain, permanent disability and social stigma associated with disfiguring visible manifestations. as a result, patients suffer mental, social and financial losses. it is estimated that 860 million people worldwide, mainly those in developing countries, are exposed to the risk of lf. elimination of lf is possible by stopping the spread of the infection through mdas of three types of lf treatments including dec tablets.

 

5. about eisai’s commitment to improving global access to medicines including lf elimination program

in line with its hhc philosophy, eisai is committed to improving global access to medicines over the medium-to-long term through partnership strategies that involve working with governments, international organizations, private entities and non-profit organizations.

in november 2010, eisai agreed to supply a total of 2.2 billion dec tablets to the who free of charge by 2020, as there was a global shortage of high-quality dec tablets for use in mdas. in 2012, eisai became the only japanese company to participate in the london declaration, a coordinated effort to eliminate 10 ntds and the largest public-private partnership of its kind in the field of global health. at the london declaration’s fifth anniversary event held in april 2017, eisai announced its plan to supply dec tablets continuously beyond 2020, until lf is eliminated in all endemic countries where dec tablets are needed.

eisai has supplied 2.05 billion tablets to 29 countries through the who’s elimination program (as of january 2022). furthermore, in order to support the smooth implementation of the who’s mda programs, eisai is engaging in initiatives to raise public awareness of lf in endemic countries. staff members of eisai group cooperate with the relevant representatives in endemic countries to eliminate lf as early as possible.

in addition to the above-mentioned initiatives, eisai is moving ahead with new drug development projects targeting malaria and ntds such as mycetoma and lf, based on partnerships with international non-profit organizations such as the drugs for neglected diseases initiative (dndi) and medicines for malaria venture (mmv), as well as research organizations such as liverpool school of tropical medicine, university of kentucky, and the broad institute (please refer to the table below).

furthermore, eisai co-established the global health innovative technology fund (ghit fund), japan’s first public–private partnership to advance development of new health technologies for the developing world, is a member of the world intellectual property organization (wipo) re:search consortium, an international joint enterprise for the development of treatments for ntds, malaria and tuberculosis led by wipo, is a signatory to the tuberculosis drug accelerator (tbda) partnership, and is participating in the access accelerated initiative to promote prevention and treatment of non-communicable diseases.

 

*1 mrc: medical research council (uk); *2 dod: department of defense (us); *3 mmv: medicines for malaria venture (swiss); *4 dhodh: dihydroorotate dehydrogenase; *5 aso: anti-sense oligo-nucleotide

 

for further information on eisai’s access to medicines initiatives, please visit the access to medicines page on the eisai global website:

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that presentations on a series of abstracts highlighting updates on its in-house discovered lenvatinib mesylate (product name: lenvima®, the orally available kinase inhibitor, “lenvatinib”) will be given at the 2022 american society of clinical oncology (asco) gastrointestinal cancers symposium (#gi22), taking place in-person in san francisco, california, and virtually, from january 20 to 22, 2022.

at this symposium, the results of a primary analysis of a prospective clinical study evaluating transcatheter arterial chemoembolization (tace) therapy in combination strategy with lenvatinib (tactics-l) in patients with unresectable hepatocellular carcinoma (uhcc) in japan (abstract no: 417), as well as research updates on the phase iv study (stellar) to evaluate safety and tolerability of lenvatinib in patients with advanced/unresectable hepatocellular carcinoma (abstract no: tps485) and results from a clinical study to evaluate the efficacy of lenvatinib for conversion surgery in patients with uhcc (investigator-initiated study in japan, abstract no: 458), will be presented.

in addition, trial-in-progress (tip) posters from the clinical program evaluating the combination therapy of lenvatinib plus pembrolizumab (product name: keytruda®), the anti-pd-1 therapy from merck & co., inc., kenilworth, n.j., u.s.a. (known as msd outside the united states and canada), include the phase iii leap-014 study of the combination plus chemotherapy in patients with esophageal carcinoma squamous cell carcinoma (abstract no: tps367), phase iii leap-015 study of the combination plus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma (abstract no: tps369), phase iii study leap-012 of the combination plus tace in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment (abstract no: tps494), and phase ii study of the combination plus belzutifan in patients with advanced solid tumors (abstract no: tps669).

in march 2018, eisai and merck & co., inc., kenilworth, n.j., u.s.a., through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib.

eisai positions oncology as a key therapeutic area and is aiming to discover revolutionary new medicines with the potential to cure cancer. eisai will continue to create innovation in the development of new drugs based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

this release discusses investigational compounds and investigational uses for fda-approved products. it is not intended to convey conclusions about efficacy and safety. there is no guarantee that any investigational compounds or investigational uses of fda-approved products will successfully complete clinical development or gain fda approval.

 

the full list of eisai poster presentations is below.

compound
abstract no.
title / scheduled date

lenvatinib

417

transcatheter arterial chemoembolization therapy in combination strategy with lenvatinib in patients with unresectable hepatocellular carcinoma (tactics-l) in japan: primary analysis

january 21 (fri)

lenvatinib

tps485*

a multicenter, observational, phase 4 study (stellar) to evaluate the safety and tolerability of lenvatinib (len) in patients with advanced or unresectable hepatocellular carcinoma (uhcc)

january 21 (fri)

lenvatinib

458

multicenter prospective study to evaluate the efficacy of lenvatinib to achieve conversion surgery for initially unresectable hepatocellular carcinoma: lens-hcc trial (investigator-initiated study in japan)

january 22 (sat)

lenvatinib pembrolizumab

tps367*

leap-014: an open-label, randomized, phase 3 study of first-line lenvatinib plus pembrolizumab plus chemotherapy in esophageal carcinoma squamous cell carcinoma

january 20 (thu)

lenvatinib pembrolizumab

tps369*

leap-015: a randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma

january 20 (thu)

lenvatinib pembrolizumab

tps494*

leap-012 trial in progress: transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment

january 20 (thu)

lenvatinib pembrolizumab

tps669*

mk-6482-016: phase 2, open-label study of pembrolizumab plus lenvatinib and belzutifan in patients with advanced solid tumors

january 20 (thu)

* the presentation with tps (trial in progress submission) attached to the abstract number indicates that the study is in the intermediate stage, and the presentation does not report the final study results.

 

media inquiries:

public relations department,

eisai co., ltd.

81-(0)3-3817-5120

 

[notes to editors]

1about the merck & co., inc., kenilworth, n.j., u.s.a. and eisai strategic collaboration

in march 2018, eisai and merck & co., inc., kenilworth, n.j., u.s.a., known as msd outside the united states and canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvima. under the agreement, the companies will jointly develop, manufacture and commercialize lenvima, both as monotherapy and in combination with keytruda, the anti-pd-1 therapy from merck & co., inc., kenilworth, n.j., u.s.a.

in addition to ongoing clinical studies evaluating the lenvima plus keytruda combination across several different tumor types, the companies have jointly initiated new clinical studies through the leap (lenvatinib and pembrolizumab) clinical program and are evaluating the combination in more than 10 different tumor types across more than 20 clinical trials.

 

2. eisai’s focus on cancer

eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from existing in-house discovered compounds) and the driver gene mutation and aberrant splicing (leveraging rna splicing platform) as areas (ricchi) where real patient needs are still unmet, and where eisai can aim to become a frontrunner in oncology. eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these ricchi, with the aim of contributing to the cure of cancers.

keytruda® is a registered trademark of merck sharp & dohme corp., a subsidiary of merck & co., inc., kenilworth, n.j., u.s.a.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that it has entered into a license agreement granting the exclusive rights for global research, development, manufacture and sale of the investigational anticancer agent h3b-8800 to a subsidiary of roivant sciences ltd. (nasdaq: roiv, headquarters: london, u.k., “roivant”). h3b-8800 (roivant’s development code: rvt-2001) is a splicing modulator compound, discovered by eisai’s u.s. research subsidiary h3 biomedicine inc., which is undergoing development as an investigational anticancer agent.

h3b-8800 is an orally available small molecule modulator of splicing factor 3b subunit 1 (sf3b1), discovered by h3 biomedicine inc. splicing occurs to remove introns that are base sequence of pre-messenger rna (mrna), unneeded for protein synthesis, in the process of synthesizing proteins based on the genetic code. mutations in splicing factor-encoding genes are observed in multiple hematological malignancies and solid tumors. sf3b1 is a particularly frequent gene mutation in splicing factors.1,2 h3b-8800 binds to sf3b1, and demonstrated significant antitumor activity in preclinical models by modulating the disruption of mrna splicing in cancer.3 eisai and h3 biomedicine inc. are currently conducting a phase i clinical trial of h3b-8800 in the u.s. and europe in patients with myelodysplastic syndrome carrying sf3b1 mutations.

under the terms of the agreement, eisai will receive a contractual up-front payment, development, and regulatory milestone payments for h3b-8800, and will also receive a certain amount of royalties on sales revenue of h3b-8800 after the launch.

roivant is a biopharmaceutical company with a unique business model. roivant builds and launches subsidiaries, called “vants” which conduct efficient clinical development in diverse therapeutic areas. eisai believes that this license agreement with roivant will lead to the maximization of the value of h3b-8800. eisai will continue to accelerate its discovery of new medicines based on cutting-edge cancer research, as it seeks to contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families, and healthcare providers.

 

media inquiries:

public relations department,

eisai co., ltd.

81-(0)3-3817-5120

 

[notes to editors] 

1. about h3 biomedicine, inc.

h3 biomedicine, inc., a cambridge, massachusetts-based biopharmaceutical company specializing in the discovery and development of precision oncology treatments using its integrated data science, human biology and precision chemistry discovery engine with the goal of improving the lives of patients. the company was established on december 2010 as a subsidiary of eisai’s u.s. pharmaceutical operation, eisai inc. h3 biomedicine focuses on sustained long-term delivery of its pipeline, collaborating with eisai co., ltd., who provides essential research funding and access to the capabilities and resources of a global pharmaceutical company.

for more information, please visit .

 

2. about roivant

roivant’s mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the roivant platform to launch vants – nimble and focused biopharmaceutical and health technology companies.

for more information, please visit .

 

1 yoshida, et al. (2011). frequent pathway mutations of splicing machinery in myelodysplasia. nature 478(7367): 64-69. doi: 10.1038/nature10496.

seiler, et al. (2018). somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. cell reports 23(1): 282-296.e4. doi: 10.1016/j.celrep.2018.01.088.

3   seiler, et al. (2018). h3b-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers. nature medicine 24(4): 497-504. doi: 10.1038/nm.4493.

first approval in japan for the lenvima plus keytruda combination

 

tokyo and kenilworth, n.j., december 24, 2021 – eisai (headquarters: tokyo, ceo: haruo naito) and merck & co., inc., kenilworth, n.j., u.s.a. (known as msd outside the united states and canada) today announced that the japanese ministry of health, labour and welfare (mhlw) has approved the combination of lenvima, the orally available multiple receptor tyrosine kinase inhibitor discovered by eisai, plus keytruda, the anti-pd-1 therapy from merck & co., inc., kenilworth, n.j., u.s.a., for the treatment of patients with unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy. this approval marks the first time the combination of lenvima plus keytruda has been approved in japan. lenvima plus keytruda is now approved in japan, the u.s. and europe for certain types of advanced endometrial carcinoma.

“rates of endometrial carcinoma have been steadily increasing in japan each year1, and there are limited options for patients who are diagnosed at an advanced stage or find their disease has returned,” said dr. gregory lubiniecki, vice president, clinical research, merck & co., inc., kenilworth, n.j., u.s.a. research laboratories. “with today’s approval, patients in japan with unresectable, advanced or recurrent endometrial carcinoma now have the option of the first immunotherapy and tyrosine kinase inhibitor combination that has significantly improved overall survival and progression-free survival compared to chemotherapy.”

“this is the first approval of the lenvima plus keytruda combination in japan,” said terushige iike, president of eisai japan, senior vice president, eisai. “we thank the patients, families and healthcare providers who made this approval possible. by delivering this combination therapy, we are proud to provide patients with advanced or recurrent endometrial carcinoma an additional treatment option.”

the approval is based on results from the pivotal phase 3 study 309/keynote-775 trial, in which lenvima plus keytruda demonstrated statistically significant improvements in overall survival (os), reducing the risk of death by 38% (hr=0.62 [95% ci, 0.51-0.75]; p<0.0001), and progression-free survival (pfs), reducing the risk of disease progression or death by 44% (hr=0.56 [95% ci, 0.47-0.66]; p<0.0001), versus chemotherapy (investigator’s choice of doxorubicin or paclitaxel). the median os was 18.3 months (95% ci, 15.2-20.5) for lenvima plus keytruda versus 11.4 months (95% ci, 10.5-12.9) for chemotherapy. the median pfs was 7.2 months (95% ci, 5.7-7.6) for lenvima plus keytruda versus 3.8 months (95% ci, 3.6-4.2) for chemotherapy.

the japanese package inserts for keytruda and lenvima note that in the study 309/keynote-775 trial, adverse reactions were observed in 395 patients (97.3%) out of the safety analysis set of 406 patients (including 51 out of 52 japanese patients) receiving lenvima  plus keytruda. the most common adverse reactions were hypertension in 249 patients (61.3%), hypothyroidism in 222 patients (54.7%), diarrhea in 171 patients (42.1%), nausea in 158 patients (38.9%), decreased appetite in 151 patients (37.2%), fatigue in 113 patients (27.8%), proteinuria in 105 patients (25.9%), vomiting in 98 patients (24.1%), weight decreased in 91 patients (22.4%), arthralgia in 87 patients (21.4%) and palmar-plantar erythrodysesthesia syndrome in 84 patients (20.7%).

endometrial carcinoma begins in the inner lining of the uterus, which is known as the endometrium, and accounts for more than 90% of uterine cancers2. in japan, it is estimated there were more than 17,000 new cases of uterine cancer and more than 3,000 deaths in 2020 alone3. lenvima and keytruda have each received orphan drug designation in japan for endometrial carcinoma.

in addition to advanced endometrial carcinoma, eisai and merck & co., inc., kenilworth, n.j., u.s.a. continue to study the lenvima plus keytruda combination across several types of cancer with more than 20 clinical trials.

 

eisai co., ltd.

public relations:

81-(0)3-3817-5120

investor relations:

81-(0) 70-8688-9685

 

merck & co., inc., kenilworth, n.j., u.s.a.

media relations

melissa moody: 1-(215) 407-3536

nikki sullivan: 1-(718) 644-0730

investor relations

peter dannenbaum: 1- (908) 740-1037

raychel kruper: 1-(908) 740- 2107

 

about study 309/keynote-775 trial

the approval was based on data from study 309/keynote-775 (), a phase 3 multicenter, open-label, randomized, active-controlled study conducted in 827 patients (including 104 japanese patients) with advanced endometrial carcinoma who had been previously treated with at least one prior platinum-based chemotherapy regimen in any setting, including in the neoadjuvant and adjuvant settings. the primary efficacy outcome measures were os, and pfs as assessed by blinded independent central review (bicr) according to recist v1.1.

patients were randomized 1:1 to receive lenvima (20 mg orally once daily) plus keytruda (200 mg intravenously every three weeks) or investigator’s choice, consisting of either doxorubicin (60 mg/m2 every three weeks) or paclitaxel (80 mg/m2 given weekly, three weeks on/one week off). treatment with lenvima plus keytruda continued until recist v1.1-defined progression of disease as verified by bicr, unacceptable toxicity, or for keytruda, a maximum of 24 months. administration of lenvima plus keytruda was permitted beyond recist-defined disease progression if the treating investigator considered the patient to be deriving clinical benefit and the treatment was tolerated.

 

about lenvima® (lenvatinib) capsules

lenvima, discovered and developed by eisai, is an orally available kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (vegf) receptors vegfr1 (flt1), vegfr2 (kdr), and vegfr3 (flt4). lenvima inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (fgf) receptors fgfr1-4, the platelet derived growth factor receptor alpha (pdgfrα), kit, and ret. in syngeneic mouse tumor models, lenvima decreased tumor-associated macrophages, increased activated cytotoxic t cells, and demonstrated greater antitumor activity in combination with an anti-pd-1 monoclonal antibody compared to either treatment alone.

currently, lenvima has been approved for monotherapy as a treatment for thyroid cancer in over 75 countries including japan, in europe, china and in asia, and in the united states for locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer. in addition, lenvima has been approved for monotherapy as a treatment for unresectable hepatocellular carcinoma in over 70 countries including japan, in europe, china and in asia, and in the united states for first-line unresectable hepatocellular carcinoma. lenvima has been approved for monotherapy as a treatment for unresectable thymic carcinoma in japan. it is also approved in combination with everolimus as a treatment for renal cell carcinoma following prior antiangiogenic therapy in over 60 countries, including in europe and asia, and in the united states the treatment of adult patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. in europe, the agent was launched under the brand name kisplyx® for renal cell carcinoma. lenvima has been approved in combination with keytruda (generic name: pembrolizumab), for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc) in united states and in europe. lenvima has been approved in combination with keytruda as a treatment for advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation in the united states, and has been approved for the similar indication (including conditional approval) in over 10 countries such as canada and australia. in some regions, continued approval for this indication is contingent upon verification and description of clinical benefit in the confirmatory trials.  in europe, it has been approved in combination with keytruda (generic name: pembrolizumab) as the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation. in japan, it is approved in combination with keytruda (generic name: pembrolizumab) as the treatment of patients with unresectable advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapy.

 

about keytruda® (pembrolizumab) injection, 100mg

keytruda is an anti-programmed death receptor-1 (pd-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. keytruda is a humanized monoclonal antibody that blocks the interaction between pd-1 and its ligands, pd-l1 and pd-l2, thereby activating t lymphocytes which may affect both tumor cells and healthy cells.

merck & co., inc., kenilworth, n.j., u.s.a. has the industry’s largest immuno-oncology clinical research program. there are currently more than 1,600 trials studying keytruda across a wide variety of cancers and treatment settings. the keytruda clinical program seeks to understand the role of keytruda across cancers and the factors that may predict a patient’s likelihood of benefitting from treatment with keytruda, including exploring several different biomarkers.

 

about the eisai and merck & co., inc., kenilworth, n.j., u.s.a. strategic collaboration

in march 2018, eisai and merck & co., inc., kenilworth, n.j., u.s.a., known as msd outside the united states and canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvima. under the agreement, the companies will jointly develop, manufacture and commercialize lenvima, both as monotherapy and in combination with keytruda, the anti-pd-1 therapy from merck & co., inc., kenilworth, n.j., u.s.a.

in addition to ongoing clinical studies evaluating the lenvima plus keytruda combination across several different tumor types, the companies have jointly initiated new clinical studies through the leap (lenvatinib and pembrolizumab) clinical program and are evaluating the combination in more than 10 different tumor types across more than 20 clinical trials.

 

eisai’s focus on cancer

eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from existing in-house discovered compounds) and the driver gene mutation and aberrant splicing (leveraging rna splicing platform) as areas (ricchi) where real patient needs are still unmet, and where eisai can aim to become a frontrunner in oncology. eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these ricchi, with the aim of contributing to the cure of cancers.

 

about eisai

eisai is a leading global research and development-based pharmaceutical company headquartered in japan, with approximately 10,000 employees worldwide. we define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. we strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including oncology and neurology. in the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society’s toughest unmet needs, including neglected tropical diseases and the sustainable development goals.

for more information about eisai, please visit (for global headquarters: eisai. co., ltd.), (for u.s. headquarters: eisai, inc.) or (for europe, middle east, africa, russia, australia and new zealand headquarters: eisai europe ltd.), and connect with us on twitter (. and ) and linkedin (for and ).

 

merck & co., inc., kenilworth, n.j., u.s.a.’s focus on cancer

our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. at merck & co., inc., kenilworth, n.j., u.s.a., the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. as part of our focus on cancer, merck & co., inc., kenilworth, n.j., u.s.a. is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. we also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. for more information about our oncology clinical trials, visit .

 

about merck & co., inc., kenilworth, n.j., u.s.a.  

for over 130 years, merck & co., inc., kenilworth, n.j., u.s.a., known as msd outside of the united states and canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. we demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. today, merck & co., inc., kenilworth, n.j., u.s.a. continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as hiv and ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. for more information, visit and connect with us on , , , and .

 

forward-looking statement of merck & co., inc., kenilworth, n.j., usa

this news release of merck & co., inc., kenilworth, n.j., usa (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the u.s. private securities litigation reform act of 1995. these statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. there can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. if underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (covid-19); the impact of pharmaceutical industry regulation and health care legislation in the united states and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

the company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 annual report on form 10-k and the company’s other filings with the securities and exchange commission (sec) available at the sec’s internet site ().

 

1 yamagami w et al. clinical statistics of gynecologic cancers in japan. j gynecol oncol. 2017 mar;28(2):e32.

.

2 american cancer society, “about endometrial cancer.”

.

3 international agency for research on cancer, world health organization. “japan fact sheet.” cancer today, 2020.

.

tokyo and cambridge, mass, dec. 24, 2021 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and biogen inc. (nasdaq: biib, corporate headquarters: cambridge, massachusetts, ceo: michel vounatsos, “biogen”) announced today that lecanemab, an investigational anti-amyloid beta (aβ) protofibril antibody for the treatment of early alzheimer’s disease (ad), was granted fast track designation by the u.s. food and drug administration (fda). fda granted breakthrough therapy designation for lecanemab in june of 2021. breakthrough therapy designation and fast track designation are two fda programs that are intended to facilitate and expedite development of new drugs to address unmet medical need in the treatment of a serious or life-threatening condition such as ad and provide opportunities for frequent interactions with the fda.

in september 2021, eisai initiated a rolling submission to the fda of a biologics license application (bla) for lecanemab under the accelerated approval pathway. the bla is primarily based on clinical, biomarker and safety data from the phase 2b clinical study (study 201) in people with early ad and confirmed amyloid pathology, and non-clinical and clinical parts of the application which consists of three parts (non-clinical, clinical and cmc) have already been submitted. the lecanemab phase 2b study results demonstrated a high degree of aβ plaque lowering and consistent reduction of clinical decline across several clinical endpoints. the correlation between the extent of aβ plaque reduction and effect on clinical endpoints in study 201 further supports aβ as a surrogate endpoint that is reasonably likely to predict clinical benefit.

the lecanemab clarity ad phase 3 clinical study in early ad is ongoing and completed enrollment in march 2021 with 1,795 patients. the fda has agreed that the results of clarity ad, when completed, can serve as the confirmatory study to verify the clinical benefit of lecanemab. blinded safety data from clarity ad is included to support the ongoing rolling submission. another phase 3 clinical study, ahead 3-45, is evaluating the efficacy of treatment with lecanemab in participants with preclinical ad and elevated amyloid and in participants with early preclinical ad and intermediate amyloid. additionally, eisai has initiated a lecanemab subcutaneous dosing phase 1 study.

alzheimer’s disease is a serious, progressive and devastating disease with few treatment options. eisai and biogen are committed to bring new treatment options to people living with early ad, their families and healthcare professionals who are waiting for them as early as possible.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) today announced it has entered into an agreement with gilead sciences, inc. (headquarters: foster city, california, “gilead”) for the commercialization and distribution of filgotinib (generic name, product name: jyseleca® ), an oral, jak1 preferential inhibitor for indications of rheumatoid arthritis (ra), ulcerative colitis, and crohn’s disease in asia (south korea, chinese taiwan, hksa and singapore). in december 2019, eisai signed a partnership agreement with gilead sciences k.k. (headquarters: tokyo), a japanese subsidiary of gilead, for the distribution and co-promotion of filgotinib in japan.

under the terms of the new agreement, eisai will obtain an exclusive marketing right for filgotinib in south korea, chinese taiwan, hksa and singapore from gilead. gilead has received approval for the treatment of ra in chinese taiwan and has applied for approval of filgotinib for the treatment of ra in south korea. following approvals, eisai will take over the manufacturing and marketing licenses for filgotinib from gilead in south korea and chinese taiwan. in hksa and singapore, eisai will apply for approval for filgotinib. with this agreement, eisai will pay gilead a contractual up-front payment, as well as regulatory milestones and sales milestones.

filgotinib is a once-daily, oral, jak1 preferential inhibitor. in japan, filgotinib has been approved for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have had an inadequate response to conventional therapies. in april 2021, gilead sciences k.k. applied for an additional indication of filgotinib as a treatment for patients with moderate to severe active ulcerative colitis.

eisai will leverage its strong business foundation throughout asia, provide new treatment options for patients with rheumatoid arthritis and inflammatory bowel disease, and contribute further to addressing the diverse needs of, and increasing the benefits provided to, patients their families, and healthcare providers.

developing solutions such as smartphones equipped with the brain health check tool “nouknow®”

 

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and fcnt limited (headquarters: kanagawa, ceo: katsumi takada, “fcnt”) announced today that both companies have entered into a business alliance agreement aiming to support people living with dementia and to prevent dementia, through developing solutions for maintaining brain performance. both companies will construct an ecosystem with the aim of supporting people living with and preventing dementia (“dementia ecosystem”), with integrating eisai’s wealth of experience and knowledge including drug creation and disease awareness activities as well as eisai’s solution measures such as digital technology, in the area of dementia, and fcnt’s products such as smartphones designed to offer outstanding usability for the elderly as well as fcnt’s services including “raku raku community” on sns targeting such smartphone users. with constructing a “dementia ecosystem”, both companies aim to contribute to the solution of dementia, which is one of the important social issues in an aging society.

the initiatives planned under the alliance are as follows.

1. the “nouknow®” will be installed on the “raku raku smartphone”

the “raku raku smartphone f-52b” developed and manufactured by fcnt will be equipped with the digital tool for self-assessment of brain performance (brain health) “nouknow” (pronounced “noh-noh”, non-medical equipment) distributed by eisai. it is scheduled to be released by ntt docomo, inc. (headquarters: tokyo, “ntt docomo”) in or after february 2022. this will be the first time that “nouknow” is deployed as a function that can be operated on a smartphone. f-52b users will be provided with brain performance checks at no cost by “nouknow” up to 4 times a year.

2. developing solutions for retaining good health and the disease prevention

eisai and fcnt will develop highly convenient solutions for the prevention of dementia, such as identifying future health concerns and predicting risks, with utilizing fcnt’s healthcare information infrastructure to accumulate data available among users, including step count, step speed and heart rate, as well as its management capacity to develop membership services such as “raku-raku community” (2.4 million members as of august 2021. based on available information by fcnt), an sns service for seniors with a membership system, in addition to eisai’s know-how based on various data in the area of dementia. furthermore, the both companies aim to deploy the new solutions developed based on this alliance for corporate customer, including businesses and regional governments, as a packaged solution that combines products and services owned by not only eisai and fcnt but also other industries and organizations.

eisai and fcnt will address and resolve the social issue related to dementia, and promote co-creation of value toward realizing a healthy and long-lived society through contributing to the construction of a “dementia ecosystem” by combining the strengths of the both companies.

eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) announced today that the company will conduct a total of 42 poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (aed) perampanel (product name: fycompa®) and in-house discovered and developed e2730, an investigational novel small compound for aed and the treatment for neurological diseases, at the 75th american epilepsy society annual meeting (aes2021), to be held in chicago, illinois and virtually from december 3 to 7, 2021.

major presentations regarding perampanel include poster presentations about the analysis results from the phase iii clinical trial (freedom/study 342), which evaluated long-term efficacy and safety of the perampanel monotherapy in the open-label extension (52 weeks) for epilepsy patients with focal-onset seizures (fos) from 12 to 74 years of age without prior treatment history (poster number: 1.283). additionally, an overview of phase iii and other clinical studies (poster number: 2.218) and a real-world pooled analysis of perampanel for elderly patients (poster number: 1.215), will be presented. for e2730, a poster presentation will be given on the non-clinical study results (poster number 2.197).

perampanel is a first-in-class aed discovered by eisai’s tsukuba research laboratories. the agent is a highly selective, noncompetitive ampa receptor antagonist that is postulated to reduce neuronal hyper-excitation associated with seizures by targeting glutamate activity at ampa receptors on postsynaptic membranes. the agent is currently approved for partial onset seizures in over 70 countries including japan, the united states, china and other countries in europe and in asia. the agent is currently approved as an adjunctive therapy for primary generalized tonic-clonic seizures in over 70 countries including japan, the united states, and other countries in europe and in asia.

e2730 is a novel selective uncompetitive gat-1 (gaba transporter-1) inhibitor with a novel mechanism of action that selectively regulates activated synaptic functions, which was discovered by eisai’s tsukuba research laboratories. clinical study of e2730 for epilepsy is underway.

eisai considers neurology, including epilepsy, a therapeutic area of focus. eisai pursues its mission to provide “seizure freedom” to a greater number of patients with epilepsy. eisai remains committed further to addressing the diverse needs of, and increasing the benefits provided to, patients with epilepsy and their families.

 

■ main poster presentations

compound
poster number
planned date and time
(central standard time)
abstract title

perampanel
poster no: 1.215
poster presentation: december 4 (sat) poster discussion:12:00-14:00

the use of perampanel in elderly epilepsy patients:
pooled analysis of real-world studies

e2730
poster no: 2.197
poster presentation: december 5 (sun) poster discussion:12:00-14:00

discovery of e2730, a novel selective uncompetitive gat-1 inhibitor: in vivo characteristics

perampanel
poster no: 2.201
poster presentation: december 5 (sun) poster discussion:12:00-14:00

long-term perampanel monotherapy and health-related quality of life in patients with newly diagnosed/currently untreated recurrent focal-onset seizures (fos):
freedom study 342 extension phase

perampanel
poster no: 2.218
poster presentation: december 5 (sun) poster discussion:12:00-14:00

perampanel in elderly patients: an overview of data from studies 307, 335, 412, 342, and 506

perampanel
poster no: 3.219
poster presentation: december 6 (mon) poster discussion:12:00-13:45

perampanel for the treatment of pediatric patients in clinical practice by age category

perampanel
poster no: 1.283
virtual

long-term efficacy and safety of perampanel monotherapy in patients with newly diagnosed/currently untreated recurrent focal-onset seizures (fos):
freedom study 342 extension phase

perampanel
poster no: 2.202
virtual

long-term seizure freedom with adjunctive perampanel in patients with focal-onset and focal to bilateral tonic-clonic seizures: post hoc analysis of study 335 open-label extension (olex)

perampanel
poster no: 2.208
virtual

assessment of cognition (epitrack®) and depression (beck depression inventory-ii) following perampanel (monotherapy/first adjunctive) in patients with epilepsy enrolled in the elevate phase iv study

 

media inquiries:

public relations department,

eisai co., ltd.

81-(0)3-3817-5120

 

[notes to editors]

1. about perampanel (product name: fycompa)

perampanel is a first-in-class anti-epileptic agent (aed) discovered and developed by eisai. with epileptic seizures being mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive ampa receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at ampa receptors on postsynaptic membranes. perampanel is available in drug form to be taken once daily orally at bedtime. a tablet and fine granule formulation have been approved in japan. an oral suspension formulation and tablet have been approved in the united states and europe.

perampanel is currently approved in more than 70 countries and territories, including japan, the united states, china, and other countries in europe and in asia as an adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. in japan, the united states and china, perampanel is approved for monotherapy and adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older. in europe the approved age range has been expanded to 4 years and above.

in addition, perampanel has been approved in more than 70 countries, including the united states, japan, in europe and in asia for treatment as an adjunctive therapy for primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older. in europe the approved age range has been expanded to 7 years and above.

to date, perampanel has been used to treat more than 410,000 patients worldwide across all indications.

eisai is conducting a global phase iii clinical study (study 338) for the agent in patients with seizures associated with lennox-gastaut syndrome. in addition, eisai is conducting development of an injection formulation.

 

2. about e2730

e2730 is a novel selective uncompetitive gat-1 (gaba transporter-1) inhibitor with a novel mechanism of action that selectively regulates activated synaptic functions, which was discovered by eisai’s tsukuba research laboratories. clinical study for epilepsy is underway.

 

3. about epilepsy

epilepsy is broadly categorized by seizure type, with partial-onset seizures accounting for approximately 60% of epilepsy cases and generalized seizures accounting for approximately 40%. in a partial-onset seizure, an abnormal electrical disturbance occurs in a limited area of the brain, and may subsequently spread throughout the brain, becoming a generalized seizure (known as a secondarily generalized seizure). in a generalized seizure, abnormal electrical disturbances occur throughout the brain, and can be followed by a loss of consciousness or physical symptoms manifested throughout the whole body.

epilepsy affects approximately 3.4 million people in the united states, 1 million people in japan, 6 million people in europe, 9 million people in china, and approximately 60 million people worldwide. as approximately 30% of patients with epilepsy are unable to control their seizures with currently available aeds,* this is a disease with significant unmet medical needs. although onset occurs at any age, onset is most common in people aged 18 and younger and the elderly. as causes and clinical symptoms of pediatric epilepsy are not uniform, and prognoses can range from very positive cases to obstinate cases, special consideration for each patient is required of treatments.

*“the epilepsies and seizures: hope through research. what are the epilepsies?” national institute of neurological disorders and stroke, accessed may 24, 2016,

first combination of tyrosine kinase inhibitor with immunotherapy approved in europe for adult patients with advanced or recurrent endometrial carcinoma with disease progression on or following prior treatment with a platinum-containing therapy in any setting and who are not candidates for curative surgery or radiation

approval based on study 309/keynote-775 results demonstrating statistically significant improvements in overall survival and progression-free survival compared with chemotherapy

 

tokyo and kenilworth, n.j., november 29, 2021 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and merck & co., inc., kenilworth, n.j., u.s.a. (known as msd outside the united states and canada) today announced that the european commission has approved the combination of lenvima, the orally available multiple receptor tyrosine kinase inhibitor discovered by eisai, plus keytruda, the anti-pd-1 therapy from merck & co., inc., kenilworth, n.j., u.s.a., for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum‑containing therapy in any setting and who are not candidates for curative surgery or radiation. this marks the first combination of tyrosine kinase inhibitor with immunotherapy approved in europe for these patients with advanced or recurrent endometrial carcinoma.

the approval is based on results from the pivotal phase 3 study 309/keynote-775 trial, in which lenvima plus keytruda demonstrated statistically significant improvements in overall survival (os), reducing the risk of death by 38% (hr=0.62 [95% ci, 0.51-0.75]; p<0.0001), and progression-free survival (pfs), reducing the risk of disease progression or death by 44% (hr=0.56 [95% ci, 0.47-0.66]; p<0.0001), versus chemotherapy (investigator’s choice of doxorubicin or paclitaxel). the median os was 18.3 months for lenvima plus keytruda versus 11.4 months for chemotherapy. the median pfs was 7.2 months for lenvima plus keytruda versus 3.8 months for chemotherapy. the objective response rate (orr) was 32% (95% ci, 27-37) for patients treated with lenvima plus keytruda versus 15% (95% ci, 11-18) for patients treated with chemotherapy (p<0.0001). patients treated with lenvima plus keytruda achieved a complete response (cr) rate of 7% and partial response (pr) rate of 25% versus a cr rate of 3% and a pr rate of 12% for patients treated with chemotherapy.

“this approval is welcome news for patients in europe, and is based on the first phase 3 study evaluating an immunotherapy and tyrosine kinase inhibitor combination that showed superior overall survival for patients with advanced or recurrent endometrial cancer compared to chemotherapy,” said dr. gregory lubiniecki, vice president, clinical research, merck & co., inc., kenilworth, n.j., u.s.a. research laboratories. “regardless of mismatch repair status, patients whose endometrial cancer progresses or returns after prior platinum-containing systemic therapies now have a combination treatment option in keytruda plus lenvima that demonstrated a 38% reduction in risk of death compared to chemotherapy alone.”

“until recently, women in europe with advanced or recurrent endometrial cancer have faced a difficult prognosis and had few treatment options,” said corina dutcus, m.d., vice president, clinical research, oncology business group at eisai inc. “the approval of lenvima plus keytruda in this setting reflects the progress that we have made in our collaboration with merck & co., inc., kenilworth, n.j., u.s.a. in developing solutions for those diagnosed with difficult-to-treat cancers. we thank the patients, families and healthcare providers who made this milestone possible.”

in the study 309 trial, the most common adverse reactions of these patients (≥20%) for lenvima plus keytruda* were hypertension (63%), diarrhoea (57%), hypothyroidism (56%), nausea (51%), decreased appetite (47%), vomiting (39%), fatigue (38%), decreased weight (35%), arthralgia (33%), proteinuria (29%), constipation (27%), headache (27%), urinary tract infection (27%), dysphonia (25%), abdominal pain (23%), asthenia (23%), palmar-plantar erythrodysaesthesia syndrome (23%), stomatitis (23%), anaemia (22%), and hypomagnesaemia (20%).

this approval allows marketing of lenvima plus keytruda in all 27 eu member states plus iceland, liechtenstein, norway and northern ireland. lenvima plus keytruda is now approved by the european commission for two different types of cancer: for advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation and for the first-line treatment of adult patients with advanced renal cell carcinoma.

*according to the information listed in the smpc (summary of product characteristics)

 

about study 309/keynote-775 trial

the approval was based on data from study 309/keynote-775 (), a phase 3 multicenter, open-label, randomized, active-controlled study conducted in 827 patients with advanced endometrial carcinoma who had been previously treated with at least one prior platinum-based chemotherapy regimen in any setting, including in the neoadjuvant and adjuvant settings. participants may have received up to two platinum-containing therapies in total, as long as one was given in the neoadjuvant or adjuvant treatment setting. the study excluded patients with endometrial sarcoma, carcinosarcoma, pre-existing grade ≥3 fistula, uncontrolled bp (>150/90 mmhg), significant cardiovascular impairment or event within previous 12 months or patients who had active autoimmune disease or a medical condition that required immunosuppression. the primary efficacy outcome measures were os, and pfs as assessed by blinded independent central review (bicr) according to recist v1.1. secondary efficacy outcome measures included orr as assessed by bicr.

patients were randomized 1:1 to receive lenvima (20 mg orally once daily) plus keytruda (200 mg intravenously every three weeks) or investigator’s choice, consisting of either doxorubicin (60 mg/m2 every three weeks) or paclitaxel (80 mg/m2 given weekly, three weeks on/one week off). treatment with lenvima plus keytruda continued until recist v1.1-defined progression of disease as verified by bicr, unacceptable toxicity, or for keytruda, a maximum of 24 months. administration of lenvima plus keytruda was permitted beyond recist-defined disease progression if the treating investigator considered the patient to be deriving clinical benefit and the treatment was tolerated. a total of 121/411 (29%) of patients treated with lenvima plus keytruda received continued study therapy beyond recist-defined disease progression. the median duration of the post-progression therapy was 2.8 months. assessment of tumor status was performed every eight weeks.

 

about endometrial cancer1,2,3,4,5

endometrial cancer begins in the inner lining of the uterus, which is known as the endometrium and is the most common type of cancer in the uterus. worldwide, it was estimated there were more than 417,000 new cases and more than 97,000 deaths from uterine body cancers in 2020 (these estimates include both endometrial cancers and uterine sarcomas; more than 90% of uterine body cancers occur in the endometrium, so the actual numbers for endometrial cancer cases and deaths are slightly lower than these estimates). in japan, there were more than 17,000 new cases of uterine body cancer and more than 3,000 deaths from the disease in 2020. in europe., it is estimated there were more than 130,000 new cases of uterine body cancer and more than 29,000 deaths in 2020. the five-year relative survival rate for metastatic endometrial cancer (stage iv) is estimated to be approximately 17%.

 

about lenvima® (lenvatinib) capsules

lenvima, discovered and developed by eisai, is an orally available kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (vegf) receptors vegfr1 (flt1), vegfr2 (kdr), and vegfr3 (flt4). lenvima inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (fgf) receptors fgfr1-4, the platelet derived growth factor receptor alpha (pdgfrα), kit, and ret. in syngeneic mouse tumor models, lenvima decreased tumor-associated macrophages, increased activated cytotoxic t cells, and demonstrated greater antitumor activity in combination with an anti-pd-1 monoclonal antibody compared to either treatment alone.

currently, lenvima has been approved for monotherapy as a treatment for thyroid cancer in over 75 countries including japan, in europe, china and in asia, and in the united states for locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer. in addition, lenvima has been approved for monotherapy as a treatment for unresectable hepatocellular carcinoma in over 70 countries including japan, in europe, china and in asia, and in the united states for first-line unresectable hepatocellular carcinoma. lenvima has been approved for monotherapy as a treatment for unresectable thymic carcinoma in japan. it is also approved in combination with everolimus as a treatment for renal cell carcinoma following prior antiangiogenic therapy in over 60 countries, including in europe and asia, and in the united states the treatment of adult patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. in europe, the agent was launched under the brand name kisplyx® for renal cell carcinoma. lenvima has been approved in combination with keytruda (generic name: pembrolizumab), for the first-line treatment of adult patients with advanced renal cell carcinoma (rcc) in united states and in europe. lenvima has been approved in combination with keytruda as a treatment for advanced endometrial carcinoma that is not microsatellite instability-high (msi-h) or mismatch repair deficient (dmmr) who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation in the united states, and has been approved for the similar indication  (including conditional approval) in over 10 countries such as canada and australia. in some regions, continued approval for this indication is contingent upon verification and description of clinical benefit in the confirmatory trials.  in europe, it is approved in combination with keytruda (generic name: pembrolizumab) as the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation.

 

about keytruda® (pembrolizumab) injection, 100mg

keytruda is an anti-programmed death receptor-1 (pd-1) therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. keytruda is a humanized monoclonal antibody that blocks the interaction between pd-1 and its ligands, pd-l1 and pd-l2, thereby activating t lymphocytes which may affect both tumor cells and healthy cells.

merck & co., inc., kenilworth, n.j., u.s.a. has the industry’s largest immuno-oncology clinical research program. there are currently more than 1,600 trials studying keytruda across a wide variety of cancers and treatment settings. the keytruda clinical program seeks to understand the role of keytruda across cancers and the factors that may predict a patient’s likelihood of benefitting from treatment with keytruda, including exploring several different biomarkers.

about the eisai and merck & co., inc., kenilworth, n.j., u.s.a. strategic collaboration

in march 2018, eisai and merck & co., inc., kenilworth, n.j., u.s.a., known as msd outside the united states and canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvima. under the agreement, the companies will jointly develop, manufacture and commercialize lenvima, both as monotherapy and in combination with keytruda, the anti-pd-1 therapy from merck & co., inc., kenilworth, n.j., u.s.a.

in addition to ongoing clinical studies evaluating the lenvima plus keytruda combination across several different tumor types, the companies have jointly initiated new clinical studies through the leap (lenvatinib and pembrolizumab) clinical program and are evaluating the combination in more than 10 different tumor types across more than 20 clinical trials.

 

eisai’s focus on cancer

eisai focuses on the development of anticancer drugs, targeting the tumor microenvironment (with experience and knowledge from existing in-house discovered compounds) and the driver gene mutation and aberrant splicing (leveraging rna splicing platform) as areas (ricchi) where real patient needs are still unmet, and where eisai can aim to become a frontrunner in oncology. eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these ricchi, with the aim of contributing to the cure of cancers.

 

about eisai

eisai is a leading global research and development-based pharmaceutical company headquartered in japan, with approximately 10,000 employees worldwide. we define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. we strive to realize our hhc philosophy by delivering innovative products in therapeutic areas with high unmet medical needs, including oncology and neurology. in the spirit of hhc, we take that commitment even further by applying our scientific expertise, clinical capabilities and patient insights to discover and develop innovative solutions that help address society’s toughest unmet needs, including neglected tropical diseases and the sustainable development goals.

for more information about eisai, please visit (for global headquarters: eisai. co., ltd.), (for u.s. headquarters: eisai, inc.) or (for europe, middle east, africa, russia, australia and new zealand headquarters: eisai europe ltd.), and connect with us on twitter (. and ) and linkedin (for and ).

 

merck & co., inc., kenilworth, n.j., u.s.a.’s focus on cancer

our goal is to translate breakthrough science into innovative oncology medicines to help people with cancer worldwide. at merck & co., inc., kenilworth, n.j., u.s.a., the potential to bring new hope to people with cancer drives our purpose and supporting accessibility to our cancer medicines is our commitment. as part of our focus on cancer, merck & co., inc., kenilworth, n.j., u.s.a. is committed to exploring the potential of immuno-oncology with one of the largest development programs in the industry across more than 30 tumor types. we also continue to strengthen our portfolio through strategic acquisitions and are prioritizing the development of several promising oncology candidates with the potential to improve the treatment of advanced cancers. for more information about our oncology clinical trials, visit .

 

about merck & co., inc., kenilworth, n.j., u.s.a.  

for over 130 years, merck & co., inc., kenilworth, n.j., u.s.a., known as msd outside of the united states and canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. we demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. today, merck & co., inc., kenilworth, n.j., u.s.a. continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as hiv and ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world. for more information, visit and connect with us on , , , and .

 

forward-looking statement of merck & co., inc., kenilworth, n.j., usa

this news release of merck & co., inc., kenilworth, n.j., usa (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the u.s. private securities litigation reform act of 1995. these statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. there can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. if underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (covid-19); the impact of pharmaceutical industry regulation and health care legislation in the united states and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

the company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2020 annual report on form 10-k and the company’s other filings with the securities and exchange commission (sec) available at the sec’s internet site ().

 

1 american cancer society, “causes, risks, prevention.” endometrial cancer.

.

2 international agency for research on cancer, world health organization. “corpus uteri fact sheet.” cancer today, 2020.

.

3 international agency for research on cancer, world health organization. “japan fact sheet.” cancer today, 2020.

.

4 american cancer society, “about and key statistics.” endometrial cancer.

.

5 american cancer society, “detection, diagnosis, staging.” endometrial cancer.

.

网站地图